+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Monoclonal Antibodies Market by Source Type (Chimeric, Human, Humanized), Production Type (In Vitro, In Vivo), Indication, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5311207
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Monoclonal Antibodies Market size was estimated at USD 126.26 billion in 2023, USD 141.81 billion in 2024, and is expected to grow at a CAGR of 12.41% to reach USD 286.43 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Monoclonal Antibodies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Monoclonal Antibodies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie, Inc., ADC Therapeutics SA, Almac Group Limited, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Source Type
    • Chimeric
    • Human
    • Humanized
    • Murine
  • Production Type
    • In Vitro
    • In Vivo
  • Indication
    • Autoimmune Diseases
    • Cancer
    • Infectious Diseases
    • Inflammatory Diseases
    • Microbial Diseases
  • End-User
    • Hospitals
    • Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Monoclonal Antibodies Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Monoclonal Antibodies Market?
  3. What are the technology trends and regulatory frameworks in the Monoclonal Antibodies Market?
  4. What is the market share of the leading vendors in the Monoclonal Antibodies Market?
  5. Which modes and strategic moves are suitable for entering the Monoclonal Antibodies Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Monoclonal Antibodies Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Rising incidence of cancer and other chronic diseases
5.1.1.3. Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
5.1.2. Restraints
5.1.2.1. Pricing of therapeutic mAbs are high
5.1.3. Opportunities
5.1.3.1. Substantial increase in the number of approvals per year
5.1.3.2. Improvements in supply chain and distribution network
5.1.4. Challenges
5.1.4.1. Limitation in current manufacturing and purification processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Monoclonal Antibodies Market, by Source Type
6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized
6.5. Murine
7. Monoclonal Antibodies Market, by Production Type
7.1. Introduction
7.2. In Vitro
7.3. In Vivo
8. Monoclonal Antibodies Market, by Indication
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Infectious Diseases
8.5. Inflammatory Diseases
8.6. Microbial Diseases
9. Monoclonal Antibodies Market, by End-User
9.1. Introduction
9.2. Hospitals
9.3. Research Institutes
10. Americas Monoclonal Antibodies Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Monoclonal Antibodies Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Monoclonal Antibodies Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. AbbVie, Inc.
14.1.3. ADC Therapeutics SA
14.1.4. Almac Group Limited
14.1.5. Amgen Inc.
14.1.6. Astellas Pharma Inc.
14.1.7. Biogen Inc.
14.1.8. Bristol Myers Squibb Company
14.1.9. Eli Lilly and Company
14.1.10. F. Hoffmann-La Roche Ltd.
14.1.11. Johnson & Johnson Services, Inc.
14.1.12. Novartis AG
14.1.13. Pfizer Inc.
14.1.14. Sanofi S.A.
14.1.15. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. MONOCLONAL ANTIBODIES MARKET SIZE, 2022 VS 2030
FIGURE 3. MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. MONOCLONAL ANTIBODIES MARKET DYNAMICS
FIGURE 7. MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2022 VS 2030 (%)
FIGURE 8. MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2022 VS 2030 (%)
FIGURE 10. MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 12. MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 14. MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 18. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 24. MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 6. MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 11. MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 14. MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 36. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 37. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 58. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 59. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 62. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 63. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 71. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 95. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 107. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 108. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 116. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 132. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 144. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 147. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 148. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 151. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 152. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 191. MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2022
TABLE 192. MONOCLONAL ANTIBODIES MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AbbVie, Inc.
  • ADC Therapeutics SA
  • Almac Group Limited
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 141.81 Billion
Forecasted Market Value ( USD ) by 2030 $ 286.43 Billion
Compound Annual Growth Rate12.4%
Regions CoveredGlobal

Related Topics

Related Reports

Global Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Forecast 2024-2030 - Product Image

Global Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Forecast 2024-2030

  • Report
  • 192 Pages
  • Global
From
Global Cancer Monoclonal Antibodies Market by Type (Chimeric, Human, Humanized), Application (Blood Cancer, Breast Cancer, Colorectal Cancer), End-user - Forecast 2024-2030 - Product Image

Global Cancer Monoclonal Antibodies Market by Type (Chimeric, Human, Humanized), Application (Blood Cancer, Breast Cancer, Colorectal Cancer), End-user - Forecast 2024-2030

  • Report
  • 188 Pages
  • Global
From
Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Global Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Forecast to 2029 - Product Image

Global Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Forecast to 2029

  • Report
  • 351 Pages
  • Global
From
Global Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2024-2032 - Product Image

Global Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From

About the Market

The Monoclonal Antibodies market is a subset of the biotechnology industry that focuses on the production and use of monoclonal antibodies (mAbs). mAbs are laboratory-produced proteins that are designed to bind to specific targets, such as proteins, cells, or tissues. They are used in a variety of applications, including diagnostics, therapeutics, and research. The market for mAbs is growing rapidly, driven by advances in biotechnology and the increasing demand for personalized medicine. mAbs are used in a variety of treatments, including cancer, autoimmune diseases, and infectious diseases. They are also used in research to develop new treatments and to improve existing treatments. The market for mAbs is highly competitive, with many companies offering a wide range of products. Major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are investing heavily in research and development to develop new mAbs and to improve existing products. In conclusion, the Monoclonal Antibodies market is an important part of the biotechnology industry, with many companies investing heavily in research and development to develop new products and improve existing treatments. Major players in the market include AbbVie, Amgen, AstraZeneca, Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.